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Abstract 
Epidemiology studies show that consumption of certain naturally occurring chemicals 
(generally plant-derived) can protect against the development of cancer (chemoprevention). 
Resveratrol, a phytoalexin found in foods such as grapes and wine as a glucoside , is one such 
chemical.  Our group has previously shown that treating mammalian cells with resveratrol 
aglycone can reduce the mutagenicity of the cooked meat-derived carcinogens 2-amino-3,8-
dimethylimidazo[4,5-f]quinoxaline (MeIQx) and 2-amino-1-methyl-6-phenylimidazo [4,5-b] 
pyridine (PhIP). However, the anti-mutagenic effect of resveratrol in vivo has not been 
previously reported. In this study, daily treatment of resveratrol up to 1000µg/kg for 10 days 
was well tolerated in Muta
TM
Mouse mice. Treating Muta
TM
Mouse mice with the meat 
carcinogen 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine induced mutation in the 
colon. Co-treatment of resveratrol and PhIP reduced the mutation frequency induced by PhIP 
in the colon by about 25% in a treatment group of mixed male and females. Analysing males 
and females separately revealed a sex difference in the response to PhIP and to the effect of 
resveratrol on PhIP-induced mutagenicity. In males compared to females, PhIP was a more 
potent colonic mutagen and resveratrol was more effective at attenuating the mutagenic 
response ( ~35% in males but only 9% in females). The reason for this sex difference in both 
PhIP mutagenicity and response to resveratrol is not clear. However, resveratrol treatment 
was also shown to powerfully inhibit ethoxyresorufin-O-deethylase activity in vivo, 
indicating that the antimutagenic affects are likely linked to metabolic activation of PhIP. 
These data suggest that resveratrol has anti-mutagenic effects in vivo, supporting its potential 
to act as a chemopreventative. 
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Introduction 
There is increasing interest in trying to prevent cancer through the administration 
(usually oral) of a chemical or chemicals that are found in the natural environment (cancer 
chemoprevention) 
1
 ; 
2
.  Resveratrol, a phytoalexin found in many human consumables such 
as grapes and red wine 
3
 shows promise as an agent of this type.  
A number of heterocyclic amines (HCAs) are formed during the routine cooking of 
red meat and meat containing products 
4
, therefore populations who consume high levels of 
red meat are potentially exposed to HCAs. To date, all of the food-derived HCAs that have 
been examined have been shown to be carcinogenic in rodents 
5
. In humans, the association 
between red meat intake and cancer, specifically cancer of the breast and colon, is well 
established and has been reported in many food-related case-control studies 
6
;  
7
; 
8
. It has 
been shown that metabolic activation of the food-derived HCA pro-mutagens is via the 
oxidation of the exocyclic amine group by cytochrome P450 (CYP) 1A family enzymes 
9
; 
10
; 
11
; 
12
. This is followed by subsequent phase II metabolism, by enzymes such as N-
acetyltransferase 
13
. Both of these metabolic steps are carried out with greater efficiency in 
human hepatic tissue than that of mice and rats 
14
.  
The most abundant HCA formed in cooked beef is PhIP
15
, thus humans are exposed 
to higher levels of this than any other HCA. PhIP is mutagenic and has been shown to induce 
mutations in both the lacZ transgene of Muta
TM
Mouse 
16
 and the lacI transgene from the 
intestine of BigBlue mice 
17
. Of the several types of mutation found in these models, 
GCTA transversions were the most abundant and a significant number of -1 guanine 
frameshifts were also noted. Many of these mutations occurred at 5’-GGA-3’ motifs. This 
pattern of mutation is very similar to that found in vitro 
18
.  
It has previously been demonstrated by our group and others that resveratrol aglycone 
can inhibit chemical-induced mutation in both bacterial and mammalian cells 
19
; 
20
. Whether 
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resveratrol can exert similar activity in vivo is not clear, however, studies suggest there are 
potential beneficial effects of resveratrol consumption. For example it has been shown that 
0.01% resveratrol aglycone in the drinking water of Apc
min
 mice (genetically predisposed to 
develop intestinal tumours) for 7 weeks decreased the formation of tumours in the small and 
large intestine by up to 70% 
21
, while in another study, administration of resveratrol aglycone 
(200 g/kg/day) in drinking water to azoxymethane-treated male F344 rats for 100 days 
decreased the formation of aberrant crypt foci in the colon 
22
. These studies therefore suggest 
that resveratrol has anti-mutagenic and anti-carcinogenic potential in vivo.  
In the current study, the mouse model Muta
TM
Mouse was used to test the hypothesis 
that resveratrol aglycone has anti-mutagenic effects in vivo, using the food-borne carcinogen 
PhIP as a model food-derived genotoxicant. The Muta
TM
Mouse model employs a bacterial 
LacZ gene as a reporter for mutation. These reporter genes have been integrated into the 
mouse chromosome, which can be recovered as phage particles. We report that treatment of 
Muta™Mouse with resveratrol aglycone attenuates the colonic mutagenicity of PhIP and that 
there is a pronounced sex difference in both the mutagenic response to PhIP and its inhibition 
by resveratrol. 
 
Material and Methods 
Chemicals 
2-Amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP, >99% purity) was purchased 
from Toronto Research Chemicals Inc (Toronto Canada).  Ethylnitrosourea (ENU, >99% 
purity), trans resveratrol aglycone (>99% purity), Luria Bertani broth (LB broth), kanamycin, 
ampicillin, phenyl -D galactosidase (P-Gal) and 5-bromo-4-chloro-3-indolyl -D-galactose 
(X-Gal) were purchased from Sigma Chemical Co. (Poole, UK). The RecoverEase
TM
DNA 
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isolation kit, RNAce ribonucleotide cocktail, proteinase K, Transpak packing extract were all 
purchased from Stratagene (La Jolla, California). 
 
Animal Husbandry 
Male CDF1 and male and female Muta
TM
Mouse mice (6-8 weeks old) weighing 20-
40 g were obtained from Covance (Harrogate, UK); bottled (public supply) water and diet 
was provided ad libitum. All animals were treated according to the Animals (Scientific 
Procedures) Act (1986), housed in a temperature and humidity controlled environment 
(20±1ºC) with 12 h of light and 12 h of darkness, and after any treatment, were checked twice 
daily for any signs of toxicity.  
 
Mutation studies using the mouse model Muta
TM
Mouse 
Animals were weighed before dosing, and the volume of ENU positive control, PhIP, 
resveratrol aglycone or vehicle negative control was calculated based on the daily weights.  
Six animals (3 male and 3 female) were dosed in each of the five treatment groups. Male and 
female Muta
TM
Mouse mice were treated as detailed in Table 1. ENU was prepared in sterile 
purified water and all PhIP and resveratrol doses were prepared in DMSO: H2O (1:1 by 
volume). All treatments were administered at 10ml/kg body weight. After treatment, a 
mutation expression period of 20 days was allowed before killing the animals by a schedule 1 
method.  
 
DNA isolation from the colon and liver of treated Muta
TM
Mouse mice 
Large molecular weight DNA from the colon and the liver was recovered using the 
Stratagene RecoverEase
TM 
DNA isolation kit.  Briefly, the tissue was washed in ice cold 
saline and 50–200 mg of complete tissue was homogenised in 8ml ice-cold lysis buffer using 
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a 7ml Wheaton Dounce tissue grinder.  The homogenate was poured through a sterile cell 
strainer and centrifuged at 1100xg for 12 min at 4C.  The supernatant was discarded and 
50l digestion solution (20l RNAce ribonucleotide cocktail/ml buffer) was added to the 
remaining pellet. Immediately, 50l of pre-heated (50C) proteinase K solution was added 
and the final reaction mixture was incubated for 45 min at 50C.  After the incubation the 
reaction mixture was placed in a dialysis cup and dialysed against TE buffer (10 mM Tris-Cl, 
pH 7.4, 1 mM EDTA; 0.5 L/ tissue sample) at room temperature for 24-48h.  Following 
dialysis, hydrated total genomic DNA was recovered and stored at -20
o
C until required. 
 
Bacterial cell culture 
A culture of the bacterial strain E.Coli (LacZ, Gal E-,recA-,Kanr (gal E-,Ampr)) 23, 
prepared from a single colony on a freshly streaked plate, was grown overnight in an orbital 
incubator at 37°C, 200rpm, with LB broth (20g LB mix dissolved in 1L deionised water, 
sterilised by autoclaving), 0.2% maltose, 0.1mg/ml ampicillin and 0.02mg/ml Kanamycin. 
The following morning a ‘day culture’ was prepared from 1-2% of the ‘overnight culture’ in 
fresh LB broth and 0.2% maltose. After the bacterial cells had reached an OD600 1.0, they 
were pelleted and resuspended in fresh LB broth containing 10mM MgSO4 to give an OD600 
2.0.  The cells were kept on ice until needed. 
 
DNA packing and mutant selection 
Shuttle vectors (gt10lacZ) were rescued from the genomic DNA of the liver and 
colon and single copies packaged into bacterial phage particles, using Transpak (Stratagene) 
packing extract following the manufacturer’s instructions. One vial of Transpak packing 
extract (10µl) was used for each DNA sample.  The extract was kept on dry ice (-40°C) until 
needed. The contents of the tube were quickly thawed before use. Using a wide-bore pipette 
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tip, 5-10µl of genomic DNA (0.5-1mg/ml) was added to the thawed Transpack packing 
extract. The DNA- Transpack packing extract mixture was then incubated at 30°C for 90 
min.  After this, a further 12µl of Transpack packing extract was added to each sample and 
incubated for a further 90 min at 30°C.  After this, 500µl of sterile SM buffer (1M Tris.HCL 
pH 7.5, 10mM MgSO4, 100mM NaCl, 0.01% gelatin) was added to each packaging reaction 
and vortexed.     
The packaged phage were used to infect a culture of E. Coli (LacZ,GalE-,recA-
,Kan
r
(galE
-
,Amp
r
)) 23, which were plated out under non-selection and selection conditions.  
Selection was achieved by plating phage-absorbed bacteria onto agar containing the lactose 
analogue phenyl -D galactoside (P-Gal). Under non-selection conditions (no P-Gal), all 
phage-infected bacteria form colonies, giving a count of the total number of packaged LacZ 
genes. Confirmation of mutant LacZ genes was accomplished by “picking” individual mutant 
plaques, re-suspended in SM buffer, vortexed vigorously and an aliquot 10-15 l used to 
infect a strain of E.coli (LacZ
-
).  In the presence of 5-bromo-4-chloro-3-indolyl--D-
galactoside (X-Gal), mutant LacZ infected bacteria produced clear or light blue viral plaques.  
Non-mutants produced dark blue plaques.  The mutation frequency for each sample of DNA 
was calculated as described by Dean and Myhr 
24
 . 
 
Ethoxyresorufin O-demethylase activity. 
CD2F1 mice were given resveratrol (10, 100, 1000 µg/kg in 50 µl DMSO/H2O 1:1 
v/v) by oral gavage (po).  DMSO:water vehicle (1:1/50 µl) was used as a vehicle control. 
Half of the animals were dosed once a day until day five, and killed by cervical dislocation 
24h after the last dose.  The remaining animals continued to be dosed until day ten and killed 
on day eleven.  The liver was removed from each animal, visually examined, weighed and 
hepatic microsomes prepared and stored as previously described
9
. The ethoxyresorufin O-
8 
 
deethylase (EROD) assay was used to determine CYP1A activity
11
. The formation of 
fluorescent resorufin was measured using a Shimadzu RF 540 Spectrofluorimeter with 
excitation at 535nm and emission at 585nm.  Under these conditions, formation of resorufin 
is linear for at least 15 min and the fluorescence is proportional to the metabolic activity of 
the CYP enzymes. 
 
Statistical analysis 
 Statistical analysis was performed using ANOVA with Tukey or Dunnet’s post-test.  
 
Results 
The effect of resveratrol on PhIP-induced mutation in Muta
TM
Mouse  
The transgenic mouse model, Muta
TM
Mouse, was used to assess the anti-mutagenic 
activity of resveratrol following co-treatment with the food carcinogen PhIP. To check for 
overt signs of treatment related toxicity, observations were made on all animals prior to 
dosing and 0.5h and 2h after dosing. No distress was noted to any animal and every treatment 
was well tolerated. The colon and liver from 6 animals (3 male and 3 female) from each 
treatment group were analysed for mutation frequency (MF) at the LacZ transgene (Tables 2 
and 3).  
The colon of ENU treated positive control mice contained a large number of mutated 
transgenes (1646  350 and 1047 ± 168 10-6 (mean ± SD) plaque forming units (pfu) for 
male and female, respectively) (Table 2). In contrast the DMSO:H2O negative control had a 
much lower colonic mutation frequency (127 ± 20 and 90 ± 436 (mean ± SD) plaque forming 
units (pfu) for male and female respectively), (Table 2). ENU was also mutagenic to the liver, 
(321 ± 95 and 297 ± 177 x10
-6
 (mean ± SD) plaque forming units (pfu) for male and female, 
respectively), but much reduced compared to the colonic mutation frequency (Tables 2 and 
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3). Similarly, the DMSO:H2O negative control also had a reduced hepatic mutation frequency 
(70 ± 12 and 46 ± 4 (mean ± SD) plaque forming units (pfu) for male and female 
respectively), (Table 3). Thus for both male and females, ENU was a much less potent 
mutagen in the liver compared to the colon.   
Resveratrol (1mg/kg) administration did not significantly alter the MF in the colon 
(125  22 and 84 ± 26 10-6 pfu for male and female, respectively) or in the liver when 
compared to the DMSO:H2O vehicle control (Tables 2 and 3).  
Treatment with 20 mg/kg PhIP significantly (p<0.001) increased the MF in the colon 
both in male and female mice compared to the vehicle control group (Table 2). Moreover, the 
MF induced in the colon was 42.6% lower in female compared to male PhIP-treated mice 
(Table 2). Co-treatment of resveratrol with PhIP significantly reduced the PhIP-induced MF 
in the colon by ~35% in males (P<0.001; Table 2), however, the same comparison in females 
showed only a reduction of approximately 9% (Table 2). In the liver of treated males, the 
PhIP mutation frequency was elevated compared to the male vehicle controls, but this was 
not statistically significant and there was no effect of resveratrol on hepatic PhIP mutation 
frequency (Table 3). In females, neither PhIP, nor resveratrol nor PhIP plus resveratrol had 
any statistically significant effect on the hepatic mutation frequency (Table 3).  
 
Effect of resveratrol treatment on Ethoxyresorufin O-demethylase activity. 
CD2F1 mice (genetically similar to Muta
TM
Mouse) that were treated daily with up to 
1000µg/kg resveratrol for 5 days (group 1) or 10 days (group 2) did not show any overt signs 
of stress and the compound did not induce mortality or morbidity during the experimental 
period. Macroscopic observation of gastrointestinal and hepatic tissue did not reveal any 
gross sign of inflammation or abnormality in any treatment group. The average weight of 
each mouse in all treatment groups (1:1 DMSO:H2O control, 10 μg/kg resveratrol, 100 μg/kg 
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resveratrol, 1000 μg/ kg resveratrol) was not significantly different before or after treatment 
(data not shown).  
The effect of resveratrol treatment on hepatic microsomal EROD activity is presented 
in Figure 1. EROD activity was inhibited by greater than 50% following 5 days treatment 
with 1000 µg/kg resveratrol, and more than 40% and 95% after 10 days treatment with 100 
and 1000 µg/kg respectively, when compared to the DMSO:H2O  control. Indeed, the fact 
that EROD activity is almost completely lost after 10 days treatment with 1000 µg/kg 
resveratrol is remarkable in view of the lack of any signs of liver toxicity in the mice. The 
dose-dependent decrease in EROD (CYP1A activity) supports the suggestion that resveratrol 
or its metabolites inhibit CYP1A activity in vivo.   
 
Discussion 
Transgenic mouse models containing recoverable bacterial reporter genes for 
measurement of in vivo mutation, such as Muta
TM
Mouse, are helpful for identifying 
mutagenic chemicals. In the current study, treatment of male and female Muta
TM
Mouse mice 
with resveratrol (1 mg/kg, once daily for 10 days) was well tolerated and did not cause any 
outward distress to either sex of animal. Furthermore, despite the reputed ability of 
resveratrol to accumulate within selected tissues in the body, especially the liver 
25
, there was 
no evidence of macro-toxicity to the mice after dissection and macroscopic observation of the 
tissues (gastrointestinal tract, liver, lungs, heart, and kidneys). These observations looked for 
tissue swelling, abnormal growths, ulcerated tissue and inflammation. 
The heterocyclic amine PhIP has been shown to be mutagenic to several tissues in the 
transgenic mouse and rat models Muta
TM
Mouse and BigBlue 
16
; 
17
; 
26
; 
27
. The data presented 
in the current study show PhIP to be a potent mouse colonic mutagen under the experimental 
conditions employed. This is in agreement with the study by Lynch et al. 
16
 who showed that 
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PhIP (20 mg/kg, 4 daily doses, seven day expression period) induced a significant 5.9 fold 
increase in colonic MF and only a very marginal effect in liver.  Although the PhIP-induced 
MF observed in the colon in the current study was lower than that observed by Lynch et al. 
16
 
it has previously been suggested that a longer exposure time to the HCA can increase the 
mutagenic effect in the lacZ and lacI transgenes 
16
; 
17
 and direct comparisons are difficult 
since the experimental protocols were different. It is important to note that the apparent tissue 
selectivity of PhIP-induced mutation (colon > liver) is consistent with PhIP’s reported 
carcinogenicity; i.e. as an intestinal rather than hepatic carcinogen 
14
.   
We have previously demonstrated the anti-mutagenic effect of resveratrol following 
PhIP treatment in vitro 
20
 and the current study shows that this effect also occurs in vivo in 
Muta™Mouse. There have been no reports to date suggesting that resveratrol itself is 
mutagenic in the colon, and the data presented here confirm this. 
When male and female mice were analysed separately it was observed that PhIP 
induced approximately 50% more mutation in the colon in males compared to females. A 
significant decrease in colon MF (~35% reduction) was observed for male mice following co-
treatment with resveratrol and PhIP compared to PhIP alone, but the effect was much less in 
females (9% reduction). It is also worth noting that treatment with ENU induced a higher MF 
in male animals compared to females. Consistent with the present study, difference between 
the genders in the mutagenic potential of ENU and the heterocyclic amines have been 
previously reported 
16
; 
28
; 
29
 
30
.  The reason for this difference is not known, but is likely to be 
multifactorial and include differences in metabolism, (rate of activation versus rate of 
deactivation), toxicokinetics and the ability to repair DNA damage. It is also noteworthy that 
PhIP like resveratrol has been shown to act as a potent oestrogen 
31
 and as such might be 
expected to affect the genders differently. The potential of this latter activity to affect 
mutation and cancer has previously been reported 
32
. 
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In the current study, 1 mg/kg resveratrol, the dose used to treat the mice in vivo, was 
found to be well tolerated with no obvious clinical signs of toxicity. This is consistent with a 
number of other in vivo rodent studies that observed biological effects at resveratrol 
concentrations equal to or less than this dose 
22
. The doses of resveratrol employed here have 
been reported to be representative of concentrations that could occur through the 
consumption of red wine or red grapes 
33
. It should be noted that the natural occurrence of 
resveratrol is as glycosides. Roches-Ribalta et al 
34
 have characterised the pharmacokinetics 
of resveratrol metabolites in humans after consumption of red wine and grape extract and 
report extensive metabolism with tissue and gut microbial involvement leading to a rapid 
appearance of plasma resveratrol glucuronide and sulphate conjugates.   
It has been shown that multiple dosing of Muta™Mouse with PhIP is effective for 
genotoxicity
16
 and in support of this, data presented here show that multiple daily doses of 
20mg/kg PhIP produce an effective genotoxic response in the colon of Muta
TM
Mouse. 
Resveratrol treatment did reduce PhIP-induced mutation in the colon of Muta
TM
Mouse, 
significantly so in the colon of male animals, possibly by reducing bioactivation of PhIP 
through inhibition of CYP activity 
20
. In support of this mechanism, we examined the effect 
of resveratrol treatment on the hepatic drug metabolism activity (EROD) of CD2F1 mice 
(genetically similar to Muta
TM
Mouse). Resveratrol treatment (100 and 1000µg/kg) inhibited 
EROD activity (a marker for CYP1A activity), and this effect was potentiated following a 
longer exposure (10 days of resveratrol treatment). In support of this, in vitro studies have 
shown that resveratrol can inhibit CYP1A1 with low affinity (IC50=1.2mM) 
35
, which we 
have confirmed in CDF1 mouse microsomal preparations (data not shown). Clearly, 
attenuation of this enzyme activity could influence activation of PhIP, whose genotoxicity is 
CYP1A-mediated. In this context, it is important to note that our analysis of metabolic 
activity was determined 1 day after the last dose of resveratrol but analysis of mutagenic 
13 
 
effects was determined after an additional 20 days to achieve optimum expression of the 
transgene.  Clearly this discrepancy means that direct comparisons are not possible, but may 
imply recovery of the CYP1A activity and therefore activation of residual PhIP, may have 
occurred in the Muta
TM
Mouse study. 
The DNA-protective effect of resveratrol treatment, which has been observed in 
bacteria and mammalian cells 
20
; 
19
, may not be entirely an inhibition of mutation per se, but 
more likely a combination of adduct-formation block and a decrease in cell growth i.e. an 
inability of the mutated phenotype to proliferate. Some of the reported biological actions of 
resveratrol such as induction of apoptosis or the inhibition of ribonucleotide reductase, DNA 
polymerase and the correct functioning of the cell cycle, confirm the multiple biological 
activities of the compound, all of which may contribute to a chemopreventive effect 
3
; 
22
. 
Moreover, PhIP like resveratrol has been shown to act as a potent oestrogen 
31
 and as such 
might be expected to affect the genders differently. 
Our results show that resveratrol has anti-mutagenic properties in vivo in 
Muta™Mouse, which appears to be more potent in males than females, possibly through 
inhibition of CYP enzymes. These data support the proposal that resveratrol has potential as a 
chemopreventive agent. 
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Tables  
 
Table 1.  Summary of the dosing schedule for each Muta
TM
Mouse group. 
Group 
Number 
Day of Study 
1          2           3           4          5           6          7           8          9          10 
1 - - - - - - - - - ENU 
2 VEH VEH VEH VEH VEH VEH VEH VEH VEH VEH 
3 VEH VEH P P P P P P VEH VEH 
4 R R R R R R R R R R 
5 R R R+P  R+P R+P R+P R+P R+P R R 
ENU : ethylnitrosourea 100mg/ kg  (positive control) – ip in water 
VEH : Vehicle (50:50 DMSO & water mix) – po 
P : PhIP 20mg/ kg – po in DMSO/ H2O (1/ 1) 
R : 1mg/ kg resveratrol - po in DMSO/ H2O (1/ 1) 
R+P : 1mg/ kg resveratrol + PhIP 20mg/ kg – po in DMSO/ H2O (1/ 1) 
 
All animals were killed and necropsied on day 30 
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Table 2. The effect of treating MutaTMMouse mice with PhIP and resveratrol on individual 
mouse colonic mutation frequency. 
 
Treatment sex
a
 PFU
b
 Mutants MF
c
 MF Mean ± SD 
ENU (100mg/kg) 
 
M 
M 
M 
 
F 
F 
F 
401,440 
852,800 
587,080 
 
1,013,480 
577,800 
652,440 
753 
1549 
595 
 
1027 
519 
802 
1878 
1817 
1243 
 
1014 
898 
1230 
1646 ± 350 
 
 
 
1047 ± 168 
PhIP (20 mg/kg) 
 
M 
M 
M 
 
F 
F 
F 
642,160 
824,720 
548,600 
 
539,760 
574,340 
637,440 
409 
442 
311 
 
193 
142 
251 
637 
536 
567 
 
358 
247 
395 
580 ± 51
+§
 
 
 
 
333 ± 77
§
 
PhIP (20 mg/kg) 
 +  
Resveratrol (1 mg/kg) 
M 
M 
M 
 
F 
F 
F 
39,080 
495,040 
616,940 
 
672,160 
446,680 
487,800 
15 
182 
255 
 
187 
132 
161 
383 
368 
414 
 
279 
296 
331 
388 ± 23*
+
 
 
 
 
302 ± 26 
Resveratrol (1 mg/kg) M 
M 
M 
 
F 
F 
F 
499,200 
554,320 
681,720 
 
343,120 
727,480 
54,080 
73 
70 
69 
 
39 
44 
4 
147 
127 
102 
 
113 
60 
80 
125 ± 22 
 
 
 
84 ± 26 
Vehicle control M 
M 
M 
 
F 
F 
F 
635,960 
458,640 
704,600 
 
572,000 
3,111,680 
197,600 
95 
51 
84 
 
72 
130 
20 
150 
112 
120 
 
126 
42 
103 
127 ± 20 
 
 
 
90 ± 43 
 
a
M= Male animals, F= Female animals. 
 
c
Mutation frequency (MF) is expressed per 10
6
 plaque-forming units (pfu) b. 
* Significantly different from PhIP treatment (p<0.001) ANOVA with Tukey post test 
+
 Significantly different from same treatment female (p<0.001) 
§ Significantly different from vehicle control (DMSO/H2O; p<0.001) 
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Table 3. The effect of treating MutaTMMouse mice with PhIP and resveratrol on individual 
mouse hepatic mutation frequency. 
 
Treatment sex
a
 PFU
b
 Mutants MF
c
 MF Mean ± SD 
ENU (100mg/kg) 
 
M 
M 
M 
 
F 
F 
F 
650,280 
637,480 
519,280 
 
770,400 
24,440 
354,120 
151 
269 
160 
 
144 
5 
177 
233 
422 
309 
 
187 
203 
502 
321 ± 95
§
 
 
 
 
297 ± 177
§
 
PhIP (20 mg/kg) 
 
M 
M 
M 
 
F 
F 
F 
557,400 
635,720 
354,120 
 
370,960 
518,440 
444,200 
40 
118 
46 
 
38 
23 
38 
73 
185 
131 
 
102 
43 
87 
130 ± 56 
 
 
 
77 ± 31 
PhIP (20 mg/kg) 
 +  
Resveratrol (1 mg/kg) 
M 
M 
M 
 
F 
F 
F 
424,440 
580,840 
656,760 
 
577,000 
411,480 
245,960 
22 
71 
52 
 
41 
30 
12 
52 
121 
78 
 
71 
50 
48 
84 ± 35 
 
 
 
56 ± 13 
Resveratrol (1 mg/kg) M 
M 
M 
 
F 
F 
F 
518,440 
275,440 
855,520 
 
657,480 
306,800 
35,720 
59 
20 
35 
 
60 
20 
3 
113 
73 
40 
 
91 
63 
70 
75 ± 37 
 
 
 
75 ± 14 
Vehicle control M 
M 
M 
 
F 
F 
F 
257,400 
535,600 
659,360 
 
884,000 
368,160 
208,520 
19 
31 
54 
 
43 
17 
9 
72 
57 
81 
 
50 
46 
42 
70 ± 12 
 
 
 
46 ± 4 
 
a
M= Male animals, F= Female animals. 
 
c
Mutation frequency (MF) is expressed per 10
6
 plaque-forming units (pfu) b. 
§ Significantly different from vehicle control (DMSO/H2O; p<0.001) ANOVA with Tukey post test 
 
 
 
  
19 
 
 
0 10 100 1000
0
20
40
60
80
100
120
five days
ten days
resveratrol dose (g/ kg)
* *
*
p
e
rc
e
n
t 
o
f 
c
o
n
tr
o
l
 
 
 
Figure 1. The ethoxyresorufin O-deethylase activity (EROD) of hepatic microsomes isolated 
from CD2F1 male mice treated with resveratrol for 5 (□) and 10 (■) days.  
Resveratrol was prepared in DMSO:H2O (1:1 by volume) vehicle.  All treatments were given 
once a day by oral gavage at the doses indicated.  Animals were killed 24 h after the last 
dose.  
Results are the mean ± SD of 5 individual mice per dose.  All assays were performed in 
triplicate and were analysed for statistical significance. *  P<0.01 compared to respective 
DMSO control (one way-ANOVA with Dunnett’s post test).  
